Group 1 - The core viewpoint of the article highlights that Weigao Orthopedics held its 17th meeting of the third board of directors on December 10, 2025, to discuss the proposal for the third extraordinary shareholders' meeting in 2025 [1] - For the year 2024, Weigao Orthopedics' revenue composition is reported to be 99.85% from the medical device manufacturing industry and 0.15% from other businesses [1] - As of the time of reporting, Weigao Orthopedics has a market capitalization of 11.2 billion yuan [1]

威高骨科12月11日公告，公司董事会于2025年12月10日召开了第三届董事会第十七次会议，审议通过了 《关于补选公司第三届董事会非独立董事及聘任公司总经理的议案》，同意提名李进取为第三届董事会 非独立董事候选人，其任期自公司股东会审议通过之日起至第三届董事会任期届满之日止。同意聘任李 进取为公司总经理，自本次董事会审议通过之日起至第三届董事会任期届满为止。 ...

Group 1 - The Sci-Tech 50 Index opened lower on November 26 but later rose significantly, closing at 1315.04 points with a gain of 0.99% and a trading volume of approximately 57.58 billion yuan [1] - The Sci-Tech Comprehensive Index also increased by 0.83%, closing at 1560.57 points with a total trading volume of about 182.8 billion yuan [2] - Excluding suspended stocks, the remaining 589 stocks on the Sci-Tech board showed an average decline of 0.15% with an average turnover rate of 2.66% [2] Group 2 - Semiconductor and biopharmaceutical stocks were notably active, while aviation and software service stocks experienced the largest declines [2] - Individual stock performance included Mingwei Electronics, Changguang Huaxin, Jindike, and Dongxin Co., which all hit the daily limit up, while Kangwei Century saw the largest drop at 10.78% [2] - In terms of trading volume, Hanwujing led with 11.89 billion yuan, while ST Guandian had the lowest at 1.027 million yuan [2] Group 3 - The turnover rate for Aerospace Huanyu was the highest at 31.51%, while Weigao Orthopedics had the lowest at 0.18% [3]

Core Viewpoint - On November 21, Weigao Orthopedics experienced a decline of 3.62% in stock price, with a trading volume of 48.15 million yuan, indicating potential market volatility and investor sentiment concerns [1]. Financing Summary - On the same day, Weigao Orthopedics had a financing buy-in amount of 9.15 million yuan and a financing repayment of 15.83 million yuan, resulting in a net financing outflow of 6.68 million yuan [1]. - The total financing and securities balance as of November 21 is 142 million yuan, which accounts for 1.25% of the circulating market value, indicating a high level of financing activity compared to the past year [1]. - The company had no shares repaid in securities lending on November 21, with 300 shares sold short, amounting to 8,541 yuan at the closing price, and a securities lending balance of 15.23 million yuan, also at a high level compared to the past year [1]. Financial Performance - For the period from January to September 2025, Weigao Orthopedics reported a revenue of 1.11 billion yuan, reflecting a year-on-year growth of 2.12%, while the net profit attributable to shareholders was 207 million yuan, showing a significant increase of 26.24% [2]. - The company has distributed a total of 575 million yuan in dividends since its A-share listing, with 367 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Weigao Orthopedics reached 10,700, an increase of 18.33% from the previous period, while the average circulating shares per person decreased by 15.49% to 37,418 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest, holding 3.44 million shares, an increase of 392,000 shares from the previous period, while Penghua Medical Technology Stock A is a new entrant as the tenth largest shareholder with 1.10 million shares [3].

Core Insights - The 24th Chinese Orthopaedic Association (COA) conference showcased significant advancements in orthopedic technology, emphasizing the integration of robotics, navigation, imaging, and biomaterials under the theme "Digital Intelligence in Orthopedics" [2] - The conference attracted 20,188 registered participants and received 37,222 submissions, indicating a strong interest in orthopedic innovations [2] Group 1: Robotics and Navigation Systems - Surgical robots and navigation systems are expanding across various orthopedic fields, moving beyond joint surgeries to include spine, trauma, and sports medicine, focusing on precision and standardization [4] - Companies like Stryker, Tianzhihang, and others are presenting comprehensive orthopedic platforms that integrate imaging, navigation, and robotic arms, forming a closed-loop system for enhanced surgical outcomes [4] - The Trinity system by Tuo Dao Medical demonstrates a unified platform for rapid switching between surgical procedures, showcasing advancements in AI planning and real-time navigation [19] Group 2: Biomaterials and Bone Repair - The competition in bone repair and biomaterials is intensifying, with companies offering innovative solutions such as absorbable screws and 3D-printed bioceramics, focusing on osteogenic activity and infection resistance [4] - Smartbone and other manufacturers are introducing advanced materials that not only fill defects but also promote bone regeneration and integration [4] Group 3: Domestic Innovations - Domestic companies are accelerating the development of high-end joint prosthetics and key materials, with a focus on integrating materials, prosthetic design, and manufacturing processes [4] - The collaboration between local firms and international companies is shifting from product showcases to establishing standards and ecosystems, enhancing the overall orthopedic landscape [4] Group 4: Key Product Launches - Stryker highlighted its latest products, including the Mako robotic system, which integrates multiple surgical techniques for hip and knee replacements, enhancing precision and efficiency [5][7] - Rosenboht signed a strategic partnership with the Chinese University of Hong Kong to advance intelligent surgical technologies, aiming for more precise and minimally invasive orthopedic procedures [12][14] - The launch of the "Panshi Self-Pressing 3D Partition Bone Trabecular Biological Knee Prosthesis" by Jiashite Medical showcases advancements in mechanical stability and biological fixation [40][42] Group 5: Technological Integration - Companies are increasingly focusing on integrating AI and imaging technologies to enhance surgical precision and safety, as seen in the solutions presented by Meiya Optical and other firms [46][50] - The introduction of AR navigation systems by Linyan Medical represents a significant technological advancement, improving the visibility and accuracy of spinal surgeries [53][55] Group 6: Comprehensive Solutions - The conference highlighted the importance of comprehensive solutions that encompass preoperative planning, intraoperative guidance, and postoperative evaluation, as demonstrated by various exhibitors [4][60] - Companies like Weigao and others are showcasing integrated solutions that leverage digital technologies to enhance the entire orthopedic treatment process [100][102]

近日，威高骨科发布公告称，公司董事、总经理卢均强因工作调整辞去公司第三届董事会董事及总经理 职务。副总经理李进取将代行总经理职责，直至董事会选聘新任总经理。卢均强辞职后，将继续在公司 控股股东、实际控制人控制的企业内任职。 截至本公告披露日，卢均强先生通过威海弘阳瑞信息技术中心（有限合伙）持有公司0.10%的股份。卢 均强辞去公司董事和高管职务后，将继续严格遵守《上海证券交易所科创板股票上市规则》《上市公司 股东减持股份管理暂行办法》《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》等规 定及其所作的相关承诺。 (编辑：杨燕 林辰)关键字： 医疗 （威高骨科公告） ...

Core Points - The company announced the resignation of its General Manager, Lu Junqiang, due to work adjustments, effective immediately upon submission of his resignation [1][2] - Vice General Manager, Li Jinqiu, will temporarily assume the responsibilities of the General Manager until a new appointment is made by the board [1] - Lu Junqiang will continue to hold a position in a company controlled by the major shareholder and actual controller [1] Company Governance - Lu Junqiang held 0.10% of the company's shares through Weihai Hongyang Rui Information Technology Center (Limited Partnership) [2] - The company will follow legal procedures to complete the election of a new director and the appointment of a new General Manager in accordance with relevant laws and regulations [2] - The board expressed gratitude for Lu Junqiang's contributions to the company's development during his tenure [2]

（文章来源：证券日报） 证券日报网讯 11月19日晚间，威高骨科发布公告称，公司董事会于11月19日收到公司董事、总经理卢 均强先生递交的书面辞职申请。因工作调整原因，卢均强先生不再担任公司第三届董事会董事、总经理 职务，由副总经理李进取先生代行总经理职责，直至董事会选聘新任总经理。卢均强先生将继续在公司 控股股东、实际控制人控制的企业内任职。 ...

北京商报讯（记者 丁宁）11月19日晚间，威高骨科（688161）发布公告称，公司董事会于11 月19日收 到公司董事、总经理卢均强递交的书面辞职申请。因工作调整原因，卢均强不再担任公司第三届董事会 董事、总经理职务，由副总经理李进取代行总经理职责，直至董事会选聘新任总经理。卢均强将继续在 公司控股股东、实际控制人控制的企业内任职。 ...

证券代码：688161 证券简称：威高骨科 公告编号：2025-045 截至本公告披露日，卢均强先生通过威海弘阳瑞信息技术中心（有限合伙） 持有公司 0.10%的股份。卢均强先生辞去公司董事和高管职务后，将继续严格遵 守《上海证券交易所科创板股票上市规则》《上市公司股东减持股份管理暂行办 法》《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》等规定 及其所作的相关承诺。 公司将根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规 则》及《公司章程》等相关规定，按照法定程序尽快完成公司董事的选举及总经 理的选聘等相关工作。 卢均强先生在担任公司董事、总经理期间，恪尽职守、勤勉尽责，为公司规 范运作和长远发展发挥了重要作用，公司及公司董事会对卢均强先生任职期间为 公司发展做出的贡献表示衷心感谢。 特此公告。 山东威高骨科材料股份有限公司董事会 山东威高骨科材料股份有限公司 关于公司董事、总经理工作调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 山东威高骨科材料股份有限公司（以下简称"公司"）董事会 ...